ZHOU Cai-cun, LI Wen-feng. Alectinib First-Line Treatment ALK-Positive Advanced Non-Small Cell Lung Cancer Was Significantly Better than Crizotinib[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 29-32. DOI: 10.12019/j.issn.1671-5144.2018.01.010
|
Citation:
|
ZHOU Cai-cun, LI Wen-feng. Alectinib First-Line Treatment ALK-Positive Advanced Non-Small Cell Lung Cancer Was Significantly Better than Crizotinib[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 29-32. DOI: 10.12019/j.issn.1671-5144.2018.01.010
|
ZHOU Cai-cun, LI Wen-feng. Alectinib First-Line Treatment ALK-Positive Advanced Non-Small Cell Lung Cancer Was Significantly Better than Crizotinib[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 29-32. DOI: 10.12019/j.issn.1671-5144.2018.01.010
|
Citation:
|
ZHOU Cai-cun, LI Wen-feng. Alectinib First-Line Treatment ALK-Positive Advanced Non-Small Cell Lung Cancer Was Significantly Better than Crizotinib[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 29-32. DOI: 10.12019/j.issn.1671-5144.2018.01.010
|
DownLoad: